Drug Trial Radar · NCT00069784
The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)
Last checked: Nov 19, 2026Latest source record: Jan 31, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12,537
Actual
Start
Aug 2003
Primary completion
Dec 2011
Study completion Dec 2011
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Population Health Research Institute
- First posted
- Oct 6, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of the ORIGIN study were: * To determine whether insulin glargine-mediated normoglycemia can reduce cardiovascular morbidity and/or mortality in people at high risk for vascular disease with either Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT) or early type 2 diabetes; * To determine whether omega-3 fatty acids can reduce cardiovascular mortality in people with IFG, IGT or early type 2 diabetes. The secondary objectives of the insulin glargine study were to determine if insulin glargine-mediated normoglycemia can reduce: * total mortality (all causes); * the risk of diabetic microvascular outcomes; * the rate of progression of IGT or IFG to type 2 diabetes.
Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
Interventions
insulin glargine (HOE901)Drug
Cartridges for use in a pen device, each containing 3 mL of insulin glargine 100 U/mL solution for injection
omega-3 polyunsaturated fatty acids (PUFA)Drug
Gelatin capsules (containing icosapent ethyl esters 465 mg and doconexent ethyl esters 375 mg) for oral administration
placeboDrug
Matching placebo gelatin capsules (containing olive oil) for oral administration
reusable pen device for insulin injectionDevice
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite of the First Occurrence of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI) or Nonfatal StrokeTime frame: from randomization until study cut-off date (median duration of follow-up: 6.2 years)
- Composite of the First Occurrence of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, Revascularization Procedure or Hospitalization for Heart Failure (HF)Time frame: from randomization until study cut-off date (median duration of follow-up: 6.2 years)
Locations
40 sites in 40 countries. Site status is shown where the registry gives one.
Sanofi-Aventis Administrative Office
Bridgewater, New Jersey
Sanofi-Aventis Administrative Office
Buenos Aires, Argentina
Sanofi-Aventis Administrative Office
Cove, New South Wales, Australia
Sanofi-Aventis Administrative Office
Vienna, Austria
Sanofi-Aventis Administrative Office
Minsk, Belarus
Sanofi-Aventis Administrative Office
Hamilton, Bermuda
Sanofi-Aventis Administrative Office
São Paulo, Brazil
Sanofi-Aventis Administrative Office
Laval, Quebec, Canada
Sanofi-Aventis Administrative Office
Santiago, Chile
Sanofi-Aventis Administrative Office
Beijing, China
Sanofi-Aventis Administrative Office
Cali, Colombia
Sanofi-Aventis Administrative Office
Zagreb, Croatia
Sanofi-Aventis Administrative Office
Hørsholm, Denmark
Sanofi-Aventis Administrative Office
Tatari, Estonia
Sanofi-Aventis Administrative Office
Helsinki, Finland
Sanofi-Aventis Administrative Office
Paris, France
Sanofi-Aventis Administrative Office
Berlin, Germany
Sanofi-Aventis Administrative Office
Budapest, Hungary
Sanofi-Aventis Administrative Office
Mumbai, India
Makati City
Dublin, Ireland
Sanofi-Aventis Administrative Office
Netanya, Israel
Sanofi-Aventis Administrative Office
Milan, Italy
Sanofi-Aventis Administrative Office
Riga, Latvia
Sanofi-Aventis Administrative Office
Vilnius, Lithuania
Sanofi-Aventis Administrative Office
México, Mexico
Sanofi-Aventis Administrative Office
Gouda, Netherlands
Sanofi-Aventis Administrative Office
Lysaker, Norway
Sanofi-Aventis Administrative Office
Makati City, Philippines
Sanofi-Aventis Administrative Office
Warsaw, Poland
Sanofi-Aventis Administrative Office
Bucharest, Romania
Sanofi-Aventis Aministrative Office
Moscow, Russia
Sanofi-Aventis Administrative Office
Bratislava, Slovakia
Sanofi-Aventis Administrative Office
Midrand, South Africa
Sanofi-Aventis Administrative Office
Seoul, South Korea
Sanofi-Aventis Administrative Office
Barcelona, Spain
Sanofi-Aventis Administrative Office
Bromma, Sweden
Sanofi-Aventis Administrative Office
Geneva, Switzerland
Sanofi-Aventis Administrative Office
Istanbul, Turkey (Türkiye)
Sanofi-Aventis Administrative Office
Guildford, Surrey, United Kingdom
Makati City
Caracas, Venezuela
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.